IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trail Site at Integrative Clinical Trials in New York January 22, 2026 Read More »
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site, in Richmond, Virginia January 12, 2026 Read More »
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability January 6, 2026 Read More »
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum December 19, 2025 Read More »
IGC Pharma Leverages AI PlatformMINT-AD to Uncover Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends December 19, 2025 Read More »
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines December 15, 2025 Read More »
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” December 10, 2025 Read More »
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial December 9, 2025 Read More »
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease December 2, 2025 Read More »
